Nutriband Inc. has announced a new partnership with Kindeva to develop Aversa™ Fentanyl, an innovative fentanyl patch that incorporates Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved patch. This collaboration marks a significant step towards creating a commercially viable product aimed at reducing the risk of abuse, misuse, and accidental exposure to fentanyl. With the commercial manufacturing process scale-up completed, the partnership aims to manufacture clinical supplies and file an Investigational New Drug $(IND.AU)$ application with the FDA. Aversa Fentanyl could become the first abuse-deterrent pain patch available on the market, enhancing the safety of transdermal drugs while ensuring accessibility for patients in need.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.